95 related articles for article (PubMed ID: 3329440)
1. Search for circulating immune complexes and activation of the complement system in relation to estrogen treatment.
Bukh A; Jensen HK; Andersen HJ; Eriksen PB; Møller NP
Acta Obstet Gynecol Scand; 1987; 66(8):703-8. PubMed ID: 3329440
[TBL] [Abstract][Full Text] [Related]
2. The complement fixing ability of putative circulating immune complexes in rheumatoid arthritis and its relationship to extra-articular disease.
Bourke BE; Moss IK; Mumford P; Horsfall A; Maini RN
Clin Exp Immunol; 1982 Jun; 48(3):726-32. PubMed ID: 6981475
[TBL] [Abstract][Full Text] [Related]
3. Blood changes in sex steroid hormone users. Circulating immune complexes induced by estrogens and progestogens and their relation to vascular thrombosis.
Beaumont V; Delplanque B; Lemort N; Beaumont JL
Atherosclerosis; 1982 Sep; 44(3):343-53. PubMed ID: 7150397
[TBL] [Abstract][Full Text] [Related]
4. Correlation of disease activity with circulating immune complexes (C1qbA) and complement breakdown products (C3D) in patients with systemic lupus erythematosus. A prospective study.
Swaak AJ; Groenwold J; Hannema A; Hack CE
Rheumatol Int; 1985; 5(5):215-20. PubMed ID: 3877968
[TBL] [Abstract][Full Text] [Related]
5. Detection of IgA class circulating immune complexes bound to anti-C3d antibody in patients with IgA nephropathy.
Doi T; Kanatsu K; Sekita K; Yoshida H; Nagai H; Hamashima Y
J Immunol Methods; 1984 Apr; 69(1):95-104. PubMed ID: 6371143
[TBL] [Abstract][Full Text] [Related]
6. Correlation of C3d fixing circulating immune complexes with disease activity and clinical parameters in patients with systemic lupus erythematosus.
Sekita K; Doi T; Muso E; Yoshida H; Kanatsu K; Hamashima Y
Clin Exp Immunol; 1984 Mar; 55(3):487-94. PubMed ID: 6608422
[TBL] [Abstract][Full Text] [Related]
7. Comparison of different assays for circulating immune complexes in age matched vasectomized and non-vasectomized men.
Witkin SS; Brandslund I; Svehag SE; Linnet L; møller NP
J Clin Lab Immunol; 1983 Apr; 10(4):193-7. PubMed ID: 6602887
[TBL] [Abstract][Full Text] [Related]
8. Correlations of C1q- and C3d-bearing circulating immune complexes with immunopathological disease activity in lupus nephritis patients.
Muso E; Yashiro M; Ito Y; Yoshida H; Sasayama S
Nihon Jinzo Gakkai Shi; 1994 Apr; 36(4):345-54. PubMed ID: 8022107
[TBL] [Abstract][Full Text] [Related]
9. Demonstration of apoptosis-associated cleavage products of DNA, complement activation products SC5b-9 and C3d/dg, and immune complexes CIC-C3d, CIC-IgA, and CIC-IgG in the urine of patients with membranous glomerulonephritis.
Kotnik V; Premzl A; Skoberne M; Malovrh T; Kveder R; Kaplan-Pavlovcic S; Kotnik A; Stiblar-Martincic D
Croat Med J; 2003 Dec; 44(6):707-11. PubMed ID: 14652883
[TBL] [Abstract][Full Text] [Related]
10. [Circulating immune complexes and complement breakdown products in childhood IgA nephropathy].
Tanaka C; Suhara Y; Kikkawa Y
Nihon Jinzo Gakkai Shi; 1991 Aug; 33(8):709-17. PubMed ID: 1770631
[TBL] [Abstract][Full Text] [Related]
11. A prospective study of circulating immune complexes in patients with breast cancer.
Bukh A; Aguado MT; Krarup N; Poulsen HS; Nordentoft AM; Møller NP
Int J Cancer; 1988 Mar; 41(3):364-70. PubMed ID: 3257943
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b.
Aguado MT; Lambris JD; Tsokos GC; Burger R; Bitter-Suermann D; Tamerius JD; Dixon FJ; Theofilopoulos AN
J Clin Invest; 1985 Oct; 76(4):1418-26. PubMed ID: 2932466
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of serial determinations of circulating immune complex levels in malignant melanoma.
Bukh A; Møller-Larsen A; Aguado MT; Møller-Larsen F; Møller NP
Cancer Immunol Immunother; 1988; 26(3):280-4. PubMed ID: 3260134
[TBL] [Abstract][Full Text] [Related]
14. Complement activation during an active cytomegalovirus infection after renal transplantation: due to circulating immune complexes or alternative pathway activation?
van Son WJ; van der Bij W; Tegzess AM; Anema J; van der Giessen M; van der Hem GK; Marrink J; The TH
Clin Immunol Immunopathol; 1989 Jan; 50(1 Pt 1):109-21. PubMed ID: 2535976
[TBL] [Abstract][Full Text] [Related]
15. [Elevated levels of circulating immune complexes -C3d and-C1q as a criterion for acute extraintestinal manifestations of ulcerative colitis].
Sagynbaeva VÉ; Lazebnik LB
Eksp Klin Gastroenterol; 2014; (7):18-24. PubMed ID: 25842401
[TBL] [Abstract][Full Text] [Related]
16. Circulating immune complexes and complement breakdown product C3d in glomerulonephritis and kidney transplantation.
Sølling J
Acta Pathol Microbiol Immunol Scand C; 1984 Aug; 92(4):213-20. PubMed ID: 6391086
[TBL] [Abstract][Full Text] [Related]
17. Complement activation and impaired capacity to solubilize immune complexes or to prevent their formation in essential mixed cryoglobulinemia.
Corvetta A; Spaeth PJ; Ghirelli PA; Orecchioni F; Buetler R; Montroni M; Nydegger UE
Diagn Immunol; 1983; 1(4):315-23. PubMed ID: 6333960
[TBL] [Abstract][Full Text] [Related]
18. Circulating immune complex levels measured by new ELISA kits utilizing monoclonal anti-C1q and anti-C3d antibodies correlate with clinical activities of SLE but not with those of RA.
Yoshinoya S; Mizoguchi Y; Aotsuka S; Yokohari R; Nishioka K; Miyamoto T
J Clin Lab Immunol; 1992; 38(4):161-73. PubMed ID: 11270517
[TBL] [Abstract][Full Text] [Related]
19. Primary lung cancer. A controlled study of preoperative and postoperative levels of circulating immune complexes.
Bukh A; Aguado MT; Kimose HH; Mouritzen C; Møoller NP
Cancer; 1988 May; 61(10):2033-41. PubMed ID: 3258788
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of in vivo immune complex formation and complement activation in patients receiving intravenous streptokinase.
Freysdottir J; Ormarsdottir S; Sigfusson A
Clin Exp Immunol; 1993 Nov; 94(2):286-90. PubMed ID: 8222319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
